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Abstract
Human immunodeficiency virus type 1 (HIV-1) persists in a latent state within resting CD4+ T cells of infected persons
treated with highly active antiretroviral therapy (HAART). This reservoir must be eliminated for the clearance of infection.
Using a cDNA library screen, we have identified methyl-CpG binding domain protein 2 (MBD2) as a regulator of HIV-1
latency. Two CpG islands flank the HIV-1 transcription start site and are methylated in latently infected Jurkat cells and
primary CD4+ T cells. MBD2 and histone deacetylase 2 (HDAC2) are found at one of these CpG islands during latency.
Inhibition of cytosine methylation with 5-aza-29deoxycytidine (aza-CdR) abrogates recruitment of MBD2 and HDAC2.
Furthermore, aza-CdR potently synergizes with the NF-kB activators prostratin or TNF-a to reactivate latent HIV-1. These
observations confirm that cytosine methylation and MBD2 are epigenetic regulators of HIV-1 latency. Clearance of HIV-1
from infected persons may be enhanced by inclusion of DNA methylation inhibitors, such as aza-CdR, and NF-kB activators
into current antiviral therapies.
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Introduction
In HIV-infected individuals, highly active anti-retroviral
therapy (HAART) dramatically reduces HIV-1 plasma titers [1–
3] and decreases morbidity and mortality [4]. However, a
reservoir of latent virus persists within resting CD4+ T cells [5–
8] and contributes to the reemergence of viremia upon
discontinuation of HAART [9–11]. Reactivation of latent HIV-
1, thus rendering it susceptible to HAART, is a critical component
of any strategy for HIV-1 clearance [12–14]. Transcriptional
repression is an important component of HIV-1 latency,
necessitating identification of cellular proteins that repress HIV-1
transcription and the testing of small molecules that inhibit these
cellular proteins.
In resting CD4+ T cells, HIV-1 is maintained in a latent state by
multiple factors that inhibit virus gene expression after integration
into cellular DNA. In particular, several studies have highlighted
the critical role of chromatin structure at the site of provirus
integration in repressing provirus transcription. Sequence-specific
transcription factors can recruit histone deacetylases (HDACs) and
other chromatin-modifying enzymes to the provirus promoter,
resulting in transcriptional repression and virus latency [15–19].
Interestingly, the mechanism by which virus escapes silencing by
these sequence-specific factors in a productive infection is
unknown. Additionally, resting CD4+ T cells are deficient in
transcription factors essential for HIV-1 transcription [20], and
latent virus can be reactivated by stimulation of T cell pathways
that activate these factors [5–8]. The provirus integration site can
also be a determinant of latency, either by making the provirus
susceptible to transcriptional interference from cellular genes [21–
24] or by suppressing virus transcription through the formation of
heterochromatin [25]. Post-transcriptional mechanisms affecting
the export [26] or translation [27] of HIV-1 mRNAs constitute
other blocks to HIV-1 gene expression during latency.
The resting state of CD4+ T cells and the activity of HDACs are
two of the best-understood characteristics of latency, but
stimulation of resting CD4+ T cells or inhibition of HDACs in
HIV-infected patients do not appreciably decrease the latent
reservoir when combined with HAART [28–32].
The study of latently infected cells is hampered by their rarity in
HIV-infected individuals and the lack of a marker for latent
infection. For these reasons, we developed the J-Lat cell lines as an
in vitro model of HIV-1 latency [33]. Similar to latently infected
CD4+ T cells, the J-Lat cells harbor a full-length HIV-1 genome
that is transcriptionally competent, is integrated within actively
transcribed cellular genes, and is inhibited at the transcriptional
level. Additionally, the latent provirus integrated in the J-Lat cell
lines encodes the GFP gene, providing a fluorescent marker of
HIV-1 transcriptional activity.
To identify novel mechanisms of HIV-1 latency, we have
conducted a cDNA screen in J-Lat cells for genes that reactivate
latent HIV-1. This screen identified a portion of methyl-CpG
binding domain protein 2 (MBD2), a transcriptional repressor that
binds methylated DNA. We found that the HIV-1 promoter is
hypermethylated in J-Lat cell lines and in primary CD4 T cells at
two CpG islands surrounding the HIV-1 transcriptional start site.
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Most importantly, we found that a small molecule inhibitor of
DNA methylation, 5-aza-29deoxycytidine (aza-CdR), synergizes
with NF-kB activators to promote a dramatic increase in virus
gene expression. Aza-CdR is approved for use in humans to treat
myelodysplastic syndrome [34] and may promote the reactivation
of latent HIV-1 and the clearance of latently-infected cells in
combination with HAART in HIV-infected patients.
Results
A genetic screen to identify novel regulators of HIV-1
latency
The J-Lat cells are clonal cell lines isolated after infection of
Jurkat cells with a HIV-1 virus encoding GFP. Latently infected
cells were selected that were GFP-negative at the basal state but
became GFP-positive after treatment with TNF-a. Treatment of
each cell line with TNF-a reactivated latent HIV-1 to a different
extent, depending on the cell line (Figure 1A). To identify cellular
genes that control HIV-1 latency in this system, a complementary
DNA (cDNA) library was made from the Jurkat T cell line and
cloned into a plasmid encoding the pBMN-CSI-T retrovirus
vector, which expresses tomato fluorescent protein as a marker
(Figure 1B).
To confirm that this vector mediates expression of cloned
cDNAs at a level sufficient for reactivation of latent HIV-1, a
positive control virus was produced that encodes NF-kB RelA,
which reactivates latent HIV-1 in J-Lat cells [18]. Infection of J-
Lat cell line 6.3 with the RelA-encoding virus caused a 3.5-fold
increase in HIV-1 gene expression compared to a control virus
that lacks an insert (Figure 1C).
The cDNA library was packaged into retroviral particles and
introduced into the J-Lat 6.3 cell line via infection (Table 1). GFP-
positive cells, indicative of reactivated latent HIV-1, were isolated
by fluorescence activated cell sorting (FACS). cDNA library inserts
were amplified from genomic DNA obtained from these cells by
Author Summary
Current drug therapies inhibit replication of the human
immunodeficiency virus (HIV). In patients undergoing
these therapies, the amount of HIV is reduced to an
undetectable level and HIV-related disease subsides.
However, stopping antiviral drug therapy results in the
quick return of HIV and of disease. One reason for this is
latently infected cells, in which virus replication is
temporarily halted. When drug therapy is stopped, virus
from these latently infected cells can resume infection and
spread to other cells in the patient, resulting in the return
of disease. Here, we demonstrate that one mechanism of
latency is DNA methylation, in which chemical groups
called methyl groups are added to HIV DNA. We also
identify a host protein called methyl-CpG binding domain
protein 2 (MBD2) that binds methylated HIV DNA and is an
important mediator of latency. Furthermore, we demon-
strate that a drug that inhibits DNA methylation potently
reactivates latent HIV. Novel strategies to eliminate or
reduce the latent reservoir are necessary. Our findings may
prove useful in the development of novel therapies to
efficiently reactivate latent HIV-1, thus making it suscep-
tible to current drug therapies.
Figure 1. A cDNA screen to identify novel regulators of HIV-1 latency. (A) Flow cytometry of latent HIV-1 reactivation in indicated J-Lat cell
lines after treatment with PBS or TNF-a. GFP-positive cells are indicated by gate and percentage. (B) Genome of retrovirus vector used in expression
screen. (C) Flow cytometry of latent HIV-1 reactivation in J-Lat 6.3 cells after transduction with retrovirus expression vectors marked with the tomato
fluorescent protein. Histograms indicate GFP expression after gating for tomato-positive cells.
doi:10.1371/journal.ppat.1000495.g001
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PCR with virus-specific primers (Figure S1A) and recloned into
pBMN-CSI-T.
MBD2 regulates HIV-1 latency and repression of
methylated DNA
One clone identified in this screen, MBD21345-1947, correspond-
ed to nucleotides 1345–1947 of the mRNA encoding the MBD2
transcriptional repressor (Figure S2). Importantly, the first ATG
within this clone is in frame with the authentic MBD2 initiation
codon, indicating a truncated protein corresponding to amino
acids 388 to 411 of full-length MBD2 could be translated.
MBD2 is a member of the methyl-CpG binding domain family
of proteins, which possess methyl-CpG binding domains (MBDs).
Similar to other members of this family, MBD2 specifically binds
methylated DNA and mediates transcriptional repression by
recruitment of the nucleosome remodeling and histone deacetyla-
tion (NuRD) complex that includes chromatin remodeling and
HDAC activities [35–37].
To confirm that MBD21345–1947 reactivates latent HIV-1, J-Lat
cells were transfected with an expression vector for this
polypeptide. Transfection of J-Lat 6.3 with MBD21345–1947
induced a 5-fold greater reactivation of latent HIV-1 in
comparison to an empty vector control (Figure 2A). Since
MBD2 inhibits transcription of methylated DNA [35], the
identification of a C-terminal fragment of MBD2 in our screen
indicated that this fragment inhibits endogenous MBD2 function
in a dominant-negative manner. Furthermore, identification of
this fragment implicated full-length, endogenous MBD2 in the
repression of HIV-1 transcription during latency. To establish the
role of endogenous MBD2 in HIV-1 latency, J-Lat 6.3 was
transfected with a pool of siRNAs corresponding to this factor.
This resulted in an 80 percent reduction in the level of MBD2
mRNA compared to cells transfected with a non-targeting control
siRNA pool (Figure 2B, left panel). Depletion of MBD2 resulted in
a 300 percent increase in HIV-1 mRNA compared to those
transfected with the control siRNA pool (Figure 2B, right panel).
These data demonstrate that MBD2 participates in the repression
of HIV-1 transcription during latency.
Since MBD2 inhibits transcription of methylated DNA [35], we
believed the C-terminal MBD2 fragment identified in our screen
might reactivate latent virus by inhibiting endogenous MBD2
function. To test MBD21345-1947 for this activity, we examined its
effect on transcription of methylated DNA in a heterologous
system. 293T cells were cotransfected with an expression vector for
MBD21345–1947 and with another plasmid encoding GFP under
the control of the CMV promoter (pEGFP-N1). This latter
plasmid was either methylated in vitro (meGFP) or left unmethy-
lated (GFP). Plasmid methylation was confirmed by resistance to
Hpa II cleavage (Figure S1B) and reduced GFP expression in
transfected 293T cells (Figure 2C). Importantly, cotransfection of
the MBD21345–1947 plasmid with methylated pEGFP-N1 increased
the proportion of GFP-positive cells from 58 to 72 percent
(Figure 2D, left panel). Furthermore, derepression by MBD21345–
1947 was preferential for methylated DNA, and a similar effect was
not observed with non-methylated pEGFP-N1 (Figure 2D, right
panel). These results implicate MBD2 and cytosine methylation in
the regulation of HIV-1 latency in the J-Lat system.
HIV-1 latency is associated with cytosine methylation in
provirus CpG islands
Cytosine methylation is an epigenetic modification that inhibits
transcription when CpG islands, clusters of CpG dinucleotides
proximal to a transcription start site, are hypermethylated [38]. To
determine whether the HIV-1 genome encodes CpG islands, the
methprimer program [39] was used search the HIV-1 provirus
nucleotide sequence. Two CpG islands were identified flanking the
transcription start site at positions -194 to -94 and 180 to 368
(Figure 3A). These islands overlap with two regions that were
previously shown to be nucleosome-free [40] and rich in
transcription factor binding sites [41], two features usually
associated with bona fide CpG islands [38]. To determine whether
HIV-1 CpG islands are methylated during latency, their
methylation state was analyzed by bisulfite-mediated methylcyto-
sine mapping. Figure S3 shows nucleotide sequence of the HIV-1
promoter, positions of CpG islands, and the particular CpGs
subjected to methylation analysis. We found that both CpG islands
were hypermethylated in four different J-Lat cell lines, with the
majority of CpGs methylated more than 70 percent of the time
(Figure 3B and Figure S4A–D). In sodium bisulfite-treated DNA,
cytosine was converted to thymine in greater than 99 percent of all
CpN dinucleotides (N = A, T, or C), confirming efficient bisulfite
conversion of non-methylated cytosines (Figure S5A).
Cytosine methylation recruits transcriptional repressors
to the HIV-1 promoter
MBD2 mediates transcriptional repression by acting as a bridge
between hypermethylated CpG islands and chromatin modifying
enzymes, including HDACs [42]. To test whether MBD2 is
recruited to the HIV-1 provirus in vivo, we performed chromatin
immunoprecipitation (ChIP) assays. Chromatin from J-lat cells was
incubated with MBD2 antisera and the immunoprecipitated
material analyzed by quantitative PCR for presence of HIV-1
provirus. We observed recruitment of MBD2 to CpG island 2 of
the HIV-1 genome, but observed no recruitment to CpG island 1
in comparison to a negative control (Figure 4B, first panel).
Treatment of J-Lat 6.3 with aza-CdR, an inhibitor of DNA
methylation, caused up to a 50 percent decrease in methylation,
depending on the CpG analyzed (Figure 4A and Figure S4E),
demonstrating that HIV-1 DNA methylation is reversible. It
should be noted that the data for PBS-treated J-Lat 6.3 in
Figures 3B and 4A are from the same experiment. Importantly,
MBD2 recruitment to CpG island 2 was eliminated when cytosine
methylation was inhibited by treatment of the cells with aza-CdR
(Figure 4B, second panel). Next, we tested for the presence of
HDAC2, an MBD2 cofactor, at CpG island 2 during latency.
Comparable to MBD2, HDAC2 was recruited to CpG island 2
during latency and was lost after treatment with aza-CdR
Table 1. cDNA screening.
Library complexity 1,000,000 independent
clones
Cells analyzed 15,000,000
Cells receiving cDNA insert (live gate)a 2,100,000 (14%)
Cells with reactivated HIV-1 (live gate)b 58,235
Cells with cDNA insert and reactivated HIV-1c 11,122 (19%)
cDNA clonesd 11,122
aTomato-positive cells in live gate. Percentage is consistent with single-hit
infection kinetics.
bGFP-positive cells in live gate.
cTomato-positive cells in the GFP-positive gate. Greater number of tomato-
positive cells than in live gate, indicating that GFP selection enriches for cDNAs
that reactivate latent HIV-1.
dClones that potentially reactivate latent HIV-1.
doi:10.1371/journal.ppat.1000495.t001
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(Figure 4B, third panel). In contrast, inhibition of methylation by
aza-CdR was associated with increased Sp1 recruitment to CpG
island 2 (Figure 4B, fourth panel). These data demonstrate that
during latency, multiple components of the NuRD complex
recognize the methylated HIV-1 CpG island 2 and that this
recruitment may be pharmacologically reversed.
Synergistic reactivation of latent HIV-1 by aza-CdR and
NF-kB activators
The finding that methylation of CpG islands flanking the HIV-1
transcription start site can be reversed with aza-CdR suggests that
aza-CdR could reactivate latent HIV-1. Aza-CdR alone, however,
showed little effect in terms of mean fluorescence intensity or the
proportion of GFP-positive cells (Figures 4C and 4D). As
previously observed, treatment with TNF-a reactivated latent
HIV-1 in only a fraction of the cell population ranging from 16 to
41 percent depending on the J-Lat cell line studied (Figure 1A). In
contrast, dual treatment of latently infected J-Lat clonal cell lines
(lines 6.3, 8.4, 9.2 and 15.4) with both aza-CdR and TNF-a
induced a dramatic increase in HIV-1 gene expression (Figures 4C
and 4D). Powerful synergy was observed when aza-CdR was used
at concentrations as low as 0.5 mM in combination with TNF-a or
the NF-kB activator prostratin (Figure 4E). The combination of
aza-CdR and TNF-a increased HIV-1 expression 196-, 101-, 76-,
and 47-fold over PBS-treated control cells (Figure 4D, upper panel
and Table S1). Each of these increases was nearly 20-fold greater
than the additive effect of the two reagents (Table S1). Synergistic
activation of transcription was specific for the HIV-1 promoter.
Analysis of J-Lat 6.3 by RT-PCR found that aza-CdR and TNF-a
synergistically activated HIV-1 transcription (Figure S6A, left
panel) but had only an additive effect on transcription of IkB-a,
another NF-kB-regulated gene (Figure S6A, right panel). The
same result was observed for J-Lat 8.4. Aza-CdR and TNF-a
synergistically activated HIV-1 transcription (Figure S6B, left
panel) but had only an additive effect on transcription of IkB-a
(Figure S6B, right panel). To determine if aza-CdR acts directly on
HIV-1 transcription, J-Lat cells were treated with cycloheximide
to inhibit expression of other factors. Cycloheximide activity was
confirmed by the inhibition of GFP expression after treatment of J-
Lat cells with TNF-a (Figure S6C). Under these conditions, aza-
CdR still induced HIV-1 transcription (Figure S6D), indicating
that aza-CdR acts directly upon the HIV-1 provirus. Synergistic
reactivation of latent virus was not observed when aza-CdR was
combined with the HDAC inhibitor valproic acid (VPA). Weak
Figure 2. MBD2 regulates HIV-1 latency and transcriptional repression. (A) Latent HIV-1 reactivation in J-Lat 6.3 cells after transfection with
the indicated expression plasmids and flow cytometry. Percent GFP-positive cells after gating for tomato-positive cells is shown. Experiment was
performed in triplicate and error bars represent standard deviation. (B) Transcriptional activation of latent HIV-1 in J-Lat 6.3 after transfection with a
siRNA that targets MBD2. Levels of MBD2 (left panel) or HIV-1 (right panel) mRNA were determined by reverse transcription and quantitative PCR and
normalized to those after transfection with a non-targeting control siRNA. Data are representative of three different experiments. Error bars indicate
standard deviation of qPCR results. (C) Flow cytometry of GFP expression in 293T cells that were mock transfected, transfected with methylated
pEGFP-N1 (meGFP), or with unmethylated pEGFP-N1 (GFP). Gate indicates GFP-positive cells. (D) Flow cytometry of GFP expression in 293T cells
cotransfected with methylated pEGFP-N1 (left panel) or unmethylated pEGFP-N1 (right panel) and an expression vector marked by the tomato
fluorescent protein. Tomato-positive cells were gated to measure GFP expression in populations that received a control vector lacking an insert or
one that encodes MBD21345–1947. Gates indicate GFP-positive cells.
doi:10.1371/journal.ppat.1000495.g002
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synergistic reactivation was observed when aza-CdR was com-
bined with the HDAC inhibitor suberoylanilide hydroxamic acid
(SAHA), with an effect about two-fold greater than the additive
effect of the drugs (Figure S7).
We show in four different J-Lat cell lines that near-complete
reactivation of latent HIV-1 required treatment with both an NF-
kB activator and an inhibitor of DNA methylation (Figure 4D,
lower panel). J-Lat A2 is another clone that harbors a latent HIV-
derived vector encoding only the viral promoter and Tat. In
contrast to the other cell lines analyzed here, latent virus in J-Lat
A2 did not require aza-CdR for full reactivation. TNF-a alone
reactivated the majority of latent virus in J-Lat A2 (Figures 4D,
lower panel, and 4F) [33]. These data show that treatment with a
methylation inhibitor is necessary for full reactivation of some, but
not all, J-Lat cell lines.
Cytosine methylation contributes to HIV-1 latency in a
polyclonal cell population
To confirm that cytosine methylation is regularly associated
with HIV-1 latency, a polyclonal population of latently infected
Jurkat T cells was generated by infection with virus produced from
the R7/E2/GFP clone. All HIV-1 proteins are expressed from
this full length HIV-1 molecular clone, except Nef, which is
replaced with GFP, and Env, which is suppressed by a frameshift
mutation. FACS was used to separate latently infected/uninfected
GFP-negative cells from productively infected GFP-positive cells
(Figure 5A). To compare the infection rate of this population to
that of the J-Lat cells, quantitative PCR for HIV R7/E2/GFP
sequence was performed on genomic DNA from the polyclonal
population 14 and 72 days post infection. The quantity of HIV-1
DNA was normalized to cellular DNA using PCR primers that
Figure 3. HIV-1 encodes two CpG islands that are methylated during latency. (A) Attributes of DNA surrounding HIV-1 transcript initiation
site. Initiation: Transcription initiation site within HIV-1 LTR is indicated by arrow. CpG islands: Plot of GC content of DNA surrounding initiation site.
Light grey areas indicate CpG islands 1 and 2. Vertical lines indicate CpGs. Nucleosome position: Locations of nucleosomes in HIV-1 promoter.
Enhancers: Transcription factor binding sites. (B) Bisulfite-mediated methylcytosine mapping of latent HIV-1 in J-Lat cells. CpG islands 1 and 2 and J-
Lat line are indicated. Each column represents one CpG position, with each circle in the column indicating either cytosine (open circles) or
methylcytosine (filled circles) in an independently cloned DNA molecule. Asterisks indicate cytosines with statistically significant methylation.
doi:10.1371/journal.ppat.1000495.g003
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anneal upstream of the b-actin gene. The level of HIV DNA in
these cells ranged from 9- to 14-fold less than that detected in J-Lat
cells, indicating a lower rate of infection (Figure 5B). Bisulfite-
mediated methylcytosine mapping of HIV-1 DNA from the
productive population found hypomethylation, with no detectable
methylation at most CpGs. In direct contrast, methylcytosine
mapping of the latent population found hypermethylation, with
the majority of CpGs methylated more than 68 percent of the time
(Figure 5D and Figure S4F). In sodium bisulfite-treated DNA,
cytosine was converted to thymine in greater than 99 percent of all
CpN dinucleotides (N = A, T, or C), confirming efficient bisulfite
conversion of non-methylated cytosines (Figure S5B).
Reactivation of latent HIV-1 was also examined in this
population. After approximately two months, the proportion of
cells with active HIV-1 remained stable at 0.65% (Figure 5C).
Cells were then treated with TNF-a, aza-CdR, or TNF-a plus aza-
CdR. TNF-a reactivated latent HIV-1, with a 1.5-fold greater
proportion of cells with active virus (Figure 5E). Importantly,
latent HIV-1 was also reactivated by aza-CdR alone, with a two-
fold greater proportion of cells with active virus (Figure 5D). These
observations indicate that, after infection of Jurkat cells in vitro, a
subset of latently infected cells exists that can be reactivated solely
by inhibition of DNA methylation.
HIV-1 latency is associated with cytosine methylation in
primary cells
The similarities of J-Lat cells to latently infected CD4+ T cells
have established the utility of this experimental system for
identifying and characterizing mechanisms of HIV-1 latency.
However, because J-Lat cells divide autonomously and possess
other aberrations associated with cellular transformation, cytosine
methylation was analyzed in a recently developed primary cell
model of latency [43]. In this system, naı¨ve CD4+ T cells are
purified from uninfected donors and activated under conditions
that drive them to become memory cells with either a Th1, Th2,
or non-polarized (NP) phenotype [44]. These differentiated cells
are then infected with HIV-1 and viral expression is monitored.
The phenotype of NP cells generated ex vivo (Figure S8) closely
resembles that of central memory CD4+ T cells found in vivo,
which persist for years in secondary lymphoid organs and can
differentiate into effector memory CD4+ T cells [45]. A high rate
of HIV-1 latency is observed in NP memory CD4+ T cells [43].
To determine if HIV-1 latency is associated with cytosine
methylation in primary CD4+ T cells, bisulfite-mediated methyl-
cytosine mapping was performed on CD4+ T cells activated under
NP, Th1, and Th2 polarizing conditions and infected with HIV-1.
Cells were infected with virus produced from the DHIV virus
clone [46], in which CpG island 2 is conserved. Five days post-
infection, p24gag was detected in all three subsets (Figure 6A). At
this early time point, the HIV-1 CpG island in the NP and Th1
populations was hypomethylated, with most CpGs methylated
only 0 or 10 percent of the time, respectively (Figure 6D and
Figure S4G). Significant methylation was detected in Th2 cells,
with most CpGs methylated 33 percent of the time (Figure 6D and
Figure S4G). Two weeks post-infection, NP cells had returned to a
quiescent state and HIV-1 gene expression, as measured by
intracellular p24gag expression, was low (Figure 6C, left panel).
However, stimulation with antibodies against CD3 and CD28
dramatically increased HIV-1 gene expression, indicating a large
population of latently infected cells (Figure 6C, right panel).
Importantly, CpG island methylation in latently infected NP cells
was greater than in productively infected NP cells, with the
majority of CpGs methylated 67 percent of the time (Figure 6E,
S5D, and S4G). In sodium bisulfite-treated DNA, cytosine was
converted to thymine in greater than 98 percent of all CpN
dinucleotides (N = A, T, or C), confirming efficient bisulfite
conversion of non-methylated cytosines (Figure S5C). These data
confirm that T cell quiescence is associated with methylation of
HIV-1 CpG islands and latency in memory CD4+ T cells.
Discussion
Here, we describe a novel, phenotype-based screen to identify
cellular proteins that control HIV-1 latency. This screen identified
the transcriptional repressor MBD2 and led to the discovery that
the latent HIV-1 provirus is hypermethylated in an in vitro model
for HIV-1 latency and in primary lymphocytes latently infected
with HIV-1. Based on these observations, we designed and tested a
novel strategy for reactivation of latent HIV-1 using the synergistic
activities of an inhibitor of cytosine methylation and activators of
NF-kB signaling.
HIV-1 latency is likely to be a multifactorial process and a
number of different mechanisms have been proposed to account
for the establishment and the maintenance of the latent phenotype
[13,14,20]. NF-kB signaling reactivates latent HIV [47–50], but
data reported here and elsewhere [16,51,52] indicate that a
significant proportion of latent HIV-1 remains silent when NF-kB
is activated in the J-Lat clones or other cells. We show here that
inhibiting provirus methylation leads to an almost complete
reactivation of latent HIV-1 in the J-Lat cell lines when combined
with activators of NF-kB. These data are consistent with the model
that sequence-specific transcription factors and cytosine methyla-
tion cooperate to maintain HIV-1 latency. In the latent state,
HDAC1 is recruited to the HIV-1 promoter by several sequence-
specific factors including NF-kB p50 [18], CBF-1 [19], and Yin-
Yang 1 [15]. Additionally, in microglial cells CTIP-2 has been
shown to recruit HDAC1 to the HIV-1 promoter [53]. Our new
observations demonstrate that MBD2 is also recruited to the latent
HIV-1 promoter via the second CpG island (Figure 7A). We
propose that MBD2 silences transcription by recruitment of the
Figure 4. Methylation-dependent recruitment of transcription factors and maintenance of HIV-1 latency. (A) Bisulfite-mediated
methylcytosine mapping of HIV-1 in J-Lat 6.3 cells treated with PBS (left panel) or aza-CdR (right panel). Asterisks indicate cytosines with a statistically
significant lesser level of methylation in cells treated with aza-CdR. (B) Panel 1: Chromatin immunoprecipitation analysis of MBD2 recruitment to an
unrelated DNA sequence between the b-actin and fascin-1 genes (unrelated), HIV-1 CpG island 1 (CpG1), and HIV-1 CpG island 2 (CpG2). Panels 2–4:
Chromatin immunoprecipitation analysis of MBD2, HDAC2, or Sp1 recruitment to CpG island 2 in cells treated with PBS or aza-CdR. Data are
representative of three independent experiments. Error bars indicate standard deviation of quantitative PCR results. (C) Flow cytometric analysis of
latent HIV-1 reactivation in the indicated J-Lat clones after treatment with aza-CdR, TNF-a, or aza-CdR plus TNF-a. Histograms indicate GFP
fluorescence. Gates indicate GFP-positive cells. (D) Bar graph representation of reactivation data. HIV-1 expression was normalized to control cells
treated with PBS, and either GFP fluorescence (top panel) or percentage of GFP-positive cells (bottom panel) is displayed. Results are representative
of three independent experiments. (E) Latent HIV-1 reactivation in J-Lat 6.3 treated with increasing doses of aza-CdR alone, in combination with TNF-
a, or in combination with prostratin. Data points on the y-axis represent fluorescence at 0 uM Aza-CdR. GFP fluorescence was measured by flow
cytometry and normalized to control cells treated with PBS. Error bars indicate standard deviation of three experiments. (F) Latent HIV-1 reactivation
in the J-Lat cell line A2 treated with aza-CdR, TNF-a, or aza-CdR plus TNF-a. Gate indicates GFP-positive cells.
doi:10.1371/journal.ppat.1000495.g004
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Figure 5. Cytosine methylation maintains HIV-1 latency in polyclonal Jurkat T cells. (A) Flow cytometry of Jurkat T cells infected with HIV-1
R7/E2/GFP clone. Gates indicate GFP-positive (productively infected) and GFP-negative (latently infected and uninfected) cells. (B) Quantitative PCR to
measure HIV-1 DNA in infected Jurkat cells. For polyclonal cell populations, days after infection are indicated. For J-Lat clones, cell line is indicated.
Levels of HIV-1 DNA were normalized to cellular DNA. Y-axis indicates fold over uninfected Jurkat negative control. Experiment was performed in
triplicate and error bars indicate standard deviation. (C) HIV-1 expression over time in a polyclonal population of latently infected and uninfected
Jurkat T cells. GFP fluorescence was measured by flow cytometry. The time point at which cells were treated with aza-CdR plus TNF-a is indicated on
the x-axis. (D) Bisulfite-mediated methylcytosine mapping of HIV-1 CpG islands in polyclonal Jurkat T cells that are latently infected (GFP-negative,
upper panel) or productively infected (GFP-positive, lower panel). Asterisks indicate cytosines with a statistically significant greater level of
methylation in the GFP-negative population. (E) Latent HIV-1 reactivation in a polyclonal population of latently infected and uninfected Jurkat T cells
treated with aza-CdR, TNF-a, or aza-CdR plus TNF-a. HIV-1 expression was measured by flow cytometry for GFP, and the percentage of cells that
express GFP is displayed. Error bars indicate standard deviation of three experiments.
doi:10.1371/journal.ppat.1000495.g005
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Figure 6. Cytosinemethylation is associatedwith HIV-1 latency in primary CD4+ T cells. (A) Flow cytometric analysis of HIV-1 gene expression in
CD4+ T cells productively infected under non-polarizing, Th1, or Th2 conditions. HIV-1 was detected by intracellular staining for p24gag. Gates indicate gag-
positive cells, and the percentage of positive cells is indicated. (B,C) Flow cytometric analysis of HIV-1 gene expression in (B) mock infected or (C) latently
infected CD4+ T cells under non-polarizing conditions, either at the basal state or after reactivation with antibodies against CD3 and CD28. HIV-1 was
detected by intracellular staining for p24gag. Gates indicate gag-positive cells, and the percentage of gag-positive cells is indicated. (D) Bisulfite-mediated
methylcytosine mapping of HIV-1 CpG island 2 in actively infected CD4+ T cells infected under non-polarizing, Th1, or Th2 conditions. (E) Bisulfite-mediated
methylcytosine mapping of HIV-1 CpG island 2 in latently infected CD4+ T cells stimulated under non-polarizing conditions.
doi:10.1371/journal.ppat.1000495.g006
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NuRD complex or other factors. This is supported by our finding
that another component of NuRD, HDAC2, is also recruited to
hypermethylated CpG island 2 during latency. NF-kB activation
relieves one component of the transcriptional block, causing
decreased CBF-1 [19] and NF-kB p50 homodimer recruitment to
the HIV-1 promoter, as well as increased binding of the NF-kB
RelA activator [18] (Figure 7B). Inhibition of cytosine methylation
relieves another component of the transcriptional block, causing
decreased MBD2 and HDAC2 recruitment to HIV-1 CpG island
2 (Figure 7C). The combination of NF-kB activation and
methylation inhibitors eliminates both transcriptional blocks,
causing a synergistic increase in HIV-1 transcription and
reactivating virus in the majority of cells (Figure 7D).
In polyclonal Jurkat cells, the magnitude of HIV-1 reactivation
appeared to be smaller than for the J-Lat clones. This was not,
however, because TNF-a or aza-CdR were ineffective, but
because of the small proportion of latently infected cells in this
population compared to the J-Lat cells, each of which harbor a
provirus. To ensure no more than one provirus per cell, they were
infected at a low multiplicity that left approximately 90 percent of
the cells uninfected. Quantitative PCR for HIV DNA demon-
strated the small proportion of infected cells in this population
compared to the J-Lat clones. Virus reactivation by TNF-a and
aza-CdR is highly significant, but is somewhat obscured by the
large background of GFP-negative uninfected cells.
The role of epigenetic mechanisms in suppression of HIV-1
transcription during latency has not been fully addressed to date.
Sequence-specific transcription factors contribute to latency by
recruiting HDACs and other repressors to the virus promoter.
These findings present a paradox, however, because latent virus can
be of wild-type nucleotide sequence [33], and yet transcription is
suppressed. Here, we present evidence that HIV-1 latency is also
maintained at the epigenetic level by the methylation of provirus
DNA and recruitment of MBD2. This protein brings transcriptional
repressors to methylated DNA, and the MBD21345–1947 fragment
isolated from the screen may reactivate latent HIV-1 by disrupting
the interaction of MBD2 with an interaction partner. Importantly,
after each round of DNA replication, cytosine methylation is
faithfully reproduced in a process that is directed by previously
methylated DNA [54]. Thus, identical DNA sequences can be
either active or silenced depending on their methylation status. Our
and previous findings suggest that both HDACs and cytosine
methylation contribute to HIV-1 latency, in agreement with a
growing body of evidence demonstrating cooperation between these
two gene silencing mechanisms [55,56].
The rarity of latently infected cells and the lack of a marker for
latent HIV-1 infection necessitate the use of in vitro model systems
for detailed studies of this process. Transformed cells such as the
Jurkat line may show aberrant DNA methylation patterns at
specific loci [57], possibly complicating analyses of cytosine
methylation and HIV-1 latency. However, when Jurkat cells are
infected with HIV-1 the proportion of cells that become latently
Figure 7. Molecular mechanisms of HIV-1 latency: Role of
cytosine methylation. The first 821 nucleotides of the HIV-1 genome
are shown, with genome position indicated relative to transcriptional
start site. The virus promoter is comprised of the U3, R, and U5 regions.
CpG island 2 is indicated by vertical lines, and filled circles on top of
lines indicate methyl groups. Arrow indicates HIV-1 transcriptional start
site. (A) Transcriptional repression during HIV-1 latency. Sequence-
specific factors recruit HDAC1. CpG island 2 is methylated and bound by
MBD2, which mediates transcriptional repression by recruitment of
NuRD. (B) NF-kB activation triggers loss of p50 homodimers and CBF-1
from the HIV-1 promoter, resulting in decreased HDAC recruitment and
partial reactivation of latent virus. Increased RelA (p65) recruitment has
also been reported. Effects upon Yin-Yang 1 recruitment are unknown.
(C) Treatment with aza-CdR decreases methylation of HIV-1 CpG islands,
leading to a loss of MBD2 from the HIV-1 promoter. Latent virus is
partially reactivated by removal of the methylation block. (D) Potent,
synergistic reactivation of latent virus when NF-kB activation is
combined with aza-CdR treatment. This occurs via loss of NF-kB-
responsive transcriptional repressors and MBD2 from the HIV-1
promoter.
doi:10.1371/journal.ppat.1000495.g007
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infected vs. productively infected is small, suggesting that
transformation does not result in the indiscriminate methylation
and repression of HIV-1. Furthermore, high-resolution analysis of
cytosine methylation in primary and transformed cells has found
less aberrant methylation of CpG island promoters in transformed
cells than had been previously hypothesized based on candidate
gene studies [58]. Importantly, we confirmed the association
between HIV-1 latency and cytosine methylation in a primary cell
model of HIV-1 latency.
The findings reported here, based upon a near full-length
HIV-1 with wild type LTR and Tat sequences, add to previous
studies that have used mutated forms of the HIV-1 promoter to
describe a role for methylation of HIV-1 DNA in latency [59–
61]. One report, however, has described latent HIV-1-derived
vectors, or ‘‘minigenomes,’’ that lack all virus genes except for
Tat. J-Lat clone A2 harbors exactly such a minigenome.
Importantly, these latent minigenomes are not methylated [62]
and are almost fully reactivated by TNF-a treatment, unlike the
full-length genome [33]. Apparently, screens to isolate latently
infected clones produced very different results when mini- instead
of full-length genomes were used. For the minigenomes, removal
of virus genes and repositioning of Tat out of its normal genomic
context are likely to have altered transcriptional control. This
alteration may have influenced the type of latently infected cell
recovered from the screen. The screens that produced the J-Lat
cells also selected for mechanisms that silence HIV-1 within
several days after infection. Other screens for cells that silence
HIV-1 at later time points have identified additional silencing
mechanisms [19].
Our results indicate that cytosine methylation can be an
important component of HIV-1 latency. In the case of the full-
length J-Lat clones, a high degree of cytosine methylation is
detected during latency. In the case of minigenomes such as J-Lat
A2 or that characterized by Pion et al, the persistent lack of
methylation may permit efficient reactivation by TNF-a alone.
Pion et al also describe a lack of cytosine methylation in latently
infected PBMCs, but the large proportion of productively infected
cells in the analyzed population complicates this assay.
Novel approaches are required to reactivate latent HIV-1 in
infected persons. Therapies that interfere with cytosine methyla-
tion are attractive candidates to reactivate suppressed virus and
purge the latent HIV-1 reservoir. In uninfected human subjects,
aza-CdR causes decreased CpG island methylation and reactiva-
tion of a silenced gene [63,64]. In HIV-infected individuals, a
similar decrease in methylation should be attainable and could
reactivate latent virus. Furthermore, mechanisms by which aza-
CdR induces hypomethylation are well understood [65,66] and
this pharmaceutical is approved for use in humans. Aza-CdR acts
directly upon the HIV-1 provirus, because it reactivates HIV-1
transcription in the presence of cycloheximide. HIV-1 was
reactivated to a lesser extent in this experiment, and this could
result from cellular toxicity or inhibition of an indirect component
to reactivation. Any indirect component to HIV-1 reactivation
would not, however, make aza-CdR any less effective a drug for
reactivation of latent HIV-1 in humans. Aza-CdR synergizes with
prostratin, a phorbol ester that triggers reactivation of latent HIV-
1 in the absence of T cell activation and inhibits de novo virus
infection [67]. Thus, the combination of aza-CdR and prostratin
may reactivate latent HIV-1 while minimizing additional HIV-1
infection and side effects associated with T cell activation [29].
Therefore, the inclusion of cytosine methylation inhibitors in
antiretroviral therapy could represent a significant step toward
elimination of the latent HIV-1 reservoir and clearance of virus
from infected patients.
Materials and Methods
Cell culture and drug treatment
Jurkat and J-Lat cells were cultured in RPMI (Invitrogen) with
5% FBS (Gemini Bio-Products) and 5% Fetalplex (Gemini Bio-
Products). For analysis of virus reactivation by flow cytometry,
aza-CdR (Sigma) and TNF-a (Biosource) treatments were for
24 h, after which medium was replaced. Reactivation was assayed
after an additional 48 h. For ChIP and bisulfite-mediated
methylcytosine mapping, cells were treated for 30 h with aza-
CdR. For cycloheximide experiments, cells were treated for
24 hours, either with or without 40 ng/ml cycloheximide.
Plasmid and cDNA library generation
20 mg of pEGFP-N1 (Clontech) was methylated at CpGs with
M. Sss I (New England Biolabs) according to the manufacturer’s
protocol. DNA was purified and subjected to a second round of
methylation. To generate pBMN-CSI-T, the multiple cloning site
(MCS) and GFP gene from pBMN-I-GFP (Addgene plasmid 1736)
were replaced with the MCS from pDNR-LIB (Clontech) and the
tomato fluorescent protein. Also, the human cytomegalovirus
(hCMV) immediate early promoter was inserted upstream of the
MCS. For production of RelA-expressing retrovirus, RelA was
cloned from pCMV4(hind), kindly provided by W. Greene, into a
version of pBMN-CSI-T lacking the hCMV promoter.
MBD21345–1947 was cloned into pBMN-CSI-T as part of cDNA
library generation. The cDNA library was generated using the
Creator SMART cDNA Library Construction Kit (Clontech) with
oligodT-purified (Quickprep mRNA Purification Kit, Amersham)
RNA isolated (TRIzol, Invitrogen) from Jurkat T cells. Amplified
cDNAs were cloned into pBMN-CSI-T and electroporated into E.
coli strain DH5a. The library was amplified 240,000-fold by
plating of bacteria on solid medium, and DNA was extracted from
aliquots (Plasmid Maxi Kit, Qiagen).
Plasmid transfection, cell infection, and screening
J-Lat cells were transfected by electroporation using Kit R and
program O-28 (Amaxa Biosystems). HIV-1 reactivation was assayed
by flow cytometry four days post-transfection. HIV-1 R7/E2/GFP
pseudotyped with the vesicular stomatitus virus G (VSV-G) protein
was produced by cotransfecting 293T cells with pEV1335 and a
plasmid encoding VSV-G by the calcium phosphate method.
Supernatant was harvested 48 h post-transfection and frozen at
280uC in aliquots. Aliquots were thawed, diluted 1:160, and used to
infect Jurkat T cells overnight at a multiplicity of 0.1 infectious units
per cell with 2 ml supernatant per 1 million cells. Three days post-
infection, GFP-negative and -positive cell populations were isolated
by FACS. Retrovirus pseudotyped with VSV-G was produced as
described previously [68] by cotransfection of Phoenix-ampho cells
with pBMN-CSI-T or plasmids derived thereof and a plasmid
encoding VSV-G. Supernatant was harvested 48 h post-transfec-
tion and J-Lat cells were infected overnight at a ratio of 250,000 cells
to 2 ml supernatant with centrifugation at 2500 rpm for the first
1.5 h. 293T cells were transfected by the calcium phosphate
method. Cells were cotransfected with a plasmid encoding the
tomato fluorescent protein and either methylated or unmethylated
pEGFP-N1, and the tomato-positive population was analyzed for
GFP expression. For measurement of J-Lat activation, cells were
infected with undiluted virus and analyzed by flow cytometry 2 days
post-infection. For cDNA screening, cells were infected at a
multiplicity of 0.15 infectious units per cell. GFP-positive cells were
purified by FACS two days post-infection, cultured for two days,
and genomic DNA was isolated (DNeasy Tissue Kit, Qiagen). The
cDNA inserts were amplified from genomic DNA by PCR using
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oSK57 (59-AAATGGGCGGTAGGCGTGTACGGTG-39) and
oSK58 (59-GCGGCTTCGGCCAGTAACGTTAGGG-39) as
primers, cloned into pBMN-CSI-T, and identified by determination
of nucleotide sequence (Molecular Cloning Laboratories).
Flow cytometry and FACS
Cell fluorescence was measured with the FACSCalibur or
LSRII (BD Biosciences). Cell sorting was performed with the
FACS Vantage DiVa (BD Biosciences). To phenotype CD4+ T
cells, they were stained with the following mAbs: phycoerythrin-
conjugated (PE)–anti-CD4, TC–anti-CD45RA, or PE–anti-
CXCR4 (Caltag). Flow cytometry and sorting data were analyzed
with FlowJo software (Treestar) or Cellquest (BD Biosciences), in
the case of primary cells. Analysis was restricted to the live
population, as defined by the forward versus side scatter profile.
Flowjo transforms fluorescence plots to a linear scale at the origin,
permitting intelligible display of cells with low fluorescence.
To assess intracellular p24gag expression, cells were fixed and
permeabilized with Citofix/Cytoperm (BD Biosciences). Cells
were washed with Perm/Wash buffer (BD Biosciences) and were
stained with anti-p24 antibody (AG3.0). Cells were washed with
Perm/Wash Buffer and incubated with Alexa Fluor 488 goat anti-
mouse IgG (H+L) in 100 ml of Perm/Wash buffer. Cells were
washed with Perm/Wash buffer and samples were analyzed by
flow cytometry. HIV-1 p24gag -positive gates were set by
comparison with uninfected cells treated in parallel.
Transfection of siRNAs, reverse transcription, and
quantitative PCR
J-Lat cells were transfected with siRNAs corresponding to the
MBD2 mRNA or non-targeting control siRNAs (siGENOME
SMARTpool or siCONTROL pool, Dharmacon) by electroporation
using Kit R and program O-28 (Amaxa Biosystems). Two days after
transfection of siRNAs, RNA was isolated from cells with TRIzol
Reagent (Invitrogen), treated with DNAse I (Promega), and first
strand cDNA was synthesized with reverse transcriptase (Superscript
II, Invitrogen) using a dT16 primer. Quantitative PCR was performed
with the 7900HT Sequence Detection System (Applied Biosystems)
and the 26 Hot Sybr real time PCR kit (Molecular Cloning
Laboratories), with each PCR reaction receiving 1/20 of the reverse
transcription. HIV R7/E2/GFP mRNA and DNA were assayed
using oSK1 (59-ATGGTGAGCAAGGGCGAGGAG-39) and oSK5
(59-GTGGTGCAGATGAACTTCAG-39), oligonucleotides, corre-
sponding to the GFP gene, as primers. HIV R7/E2/GFP DNA was
normalized to a DNA sequence upstream of the human b-actin gene
using 5USBACT (59-GCCAGCTGCAAGCCTTGG-39) and 3US-
BACT [18] (59-GCCACTGGGCCTCCATTC-39) as primers.
MBD2 mRNA was assayed using oSK61 (59-CCCACAACGAAT-
GAATGAACAGC-39) and oSK62 (59-TGAAGACCTTTGGG-
TAGTTCCA-39) as primers. As an internal control, HIV and
MBD2 mRNA levels were normalized to that of cyclophilin A.
Cyclophilin A mRNA was assayed using oSK6 (59-GTCT-
CCTTTGAGCTGTTTGC-39) and oSK7 (59-CCATAGATG-
GACTTGCCACC-39) as primers. IkB-a mRNA was assayed using
oSK135 (59- CTCCGAGACTTTCGAGGAAATAC-39) and
oSK136 (59- GCCATTGTAGTTGGTAGCCTTCA-39) as prim-
ers. SDS 2.3 software (Applied Biosystems) was used to quantify each
cDNA relative to cyclophilin A and to confirm the specificity of each
PCR reaction by melting curve analysis.
Bisulfite-mediated methylcytosine mapping
Sodium bisulfite treatment was performed according to the
Pikaard protocol (http://www.biology.wustl.edu/pikaard/
PDFs%20and%20protocol%20files%20/Bisulfite%20Sequencing.
pdf) with minor modifications. Jurkat T cell DNA was digested
overnight with Pst I and purified with the Qiaquick PCR
Purification Kit (Qiagen). Bisulfite-treated DNA was amplified in
nested PCR reactions with the following reaction conditions:
denature (95uC, 5 minutes), cycle 35 times (95uC, 30 seconds then
60uC, 60 seconds), and extend (60uC, 7 minutes). For J-Lat cells,
the first reaction used oSK100 (59-CGCCTCGAGTTTATTGAT-
TTTTGGATGGTGTTAT-39) and oSK101 (59-CGCTCTA-
GACCATTTACCCCTAAATATTCTACAC-39) as primers and
the second reaction used oSK71 (59-CGCCTCGAGATATT-
TTGTGAGTTTGTATGGGATG-39) and oSK94 (59-CGCTC-
TAGACCCAATATTTATCTACAA-39) as primers. For primary
cells infected with NL4-3-derived virus, the first reaction used
oSK123 (59-CGCCTCGAGTTTATTGATTTTTGGATGGTG-
TTTT-39) and oSK124 (59-CGCTCTAGACCATTTACCCC-
TAAAAATTCTACAC-39) as primers and the second reaction
used oSK122 (59-CGCCTCGAGATATTTTATGAGTTAG-
TATGGGATG-39) and oSK94 as primers. All PCR reactions
were performed in triplicate and then pooled to reduce chances of
clonality in recovered fragments. Products were cleaved with Xho I
and Xba I and cloned into pBluescript (Stratagene) cleaved with the
same enzymes. Nucleotide sequence was determined of at least nine
cloned inserts using the universal M13 reverse primer. The
efficiency of sodium bisulfite conversion was calculated using the
Quantification Tool for Methylation Analysis (QUMA) software
[69]. The nucleotide sequence of untreated DNA was also
determined to ensure that readings do not result from virus
mutations.
Statistical analyses
The effect of MBD21345–1947 upon GFP expression (Figure 2A)
was evaluated by a two-tailed, two sample Student’s t-test with a
null hypothesis of no effect. Reactivation of latent HIV-1
(Figure 5D) was evaluated with a one-tailed, two sample Student’s
t-test with a null hypothesis of no increase in GFP expression. In
bisulfite-mediated methylcytosine mapping experiments, at least
nine independent clones of sodium bisulfite-treated HIV-1 DNA
were analyzed from each sample. For J-Lat cell lines in the latent
state (Figure 3B) and CD4+ T cells (Figures 6D and E), a one-
tailed, single sample Student’s t-test was performed for each CpG
with a null hypothesis of no methylation. For J-Lat 6.3 treated with
either aza-CdR or a PBS control (Figure 4A), a one-tailed, two-
sample Student’s t-test was performed for each CpG with a null
hypothesis of no decrease in methylation after aza-CdR treatment.
For sorted populations of GFP-negative and -positive Jurkat T cells
(Figure 5B), a one-tailed, two sample Student’s t-test was
performed for each CpG with the null hypothesis that the GFP-
positive population did not have less methylation.
Chromatin immunoprecipitation and quantitative PCR
ChIP was performed as described previously [70] with
modifications. J-Lat 6.3 cells Cells were diluted to 56105 per ml,
lysed, and sonicated (Model 500 Ultrasonic Dismembranator,
Fisher Scientific). Lysates were incubated overnight with 5 mg of
antibody against MBD2 (Upstate Cell Signaling Solutions cat. 07-
198), HDAC2 (Santa Cruz Biotechnology cat. sc-7899) or Sp1
(Santa Cruz Biotechnology cat. sc-59). Immune complexes were
recovered by incubation for 1 h with protein A agarose beads
(Invitrogen). Immunoprecipitated DNA was quantified by quan-
titative PCR using the 7900HT Sequence Detection System
(Applied Biosystems) and 26 Hot Sybr real time PCR kit
(Molecular Cloning Laboratories). Negative control DNA was
assayed using 5USBACT and 3USBACT as primers, CpG island
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1 was assayed using oSK92 (59-TCAGTTCAGATAATTT-
CAGTTGTCC-39) and oSK93 (59-CCCAGTACAGG-
CAAAAAGCA-39) as primers, and CpG island 2 was assayed
using oSK89 (59-AAGCGAAAGGGAAACCAGAG-39) and
oSK90 (59-TCTCCCCCGCTTAATACTGA-39) as primers.
SDS 2.3 software (Applied Biosystems) was used to analyze
precipitated DNA relative to input and to confirm the specificity of
each PCR reaction by melting curve analysis.
Differentiation, infection, and activation of CD4+ T cells
ex vivo
PBMCs were obtained from leukopaks from unidentified, healthy
donors. Naı¨ve CD4+ T cells were isolated by MACS microbead
negative sorting using the naı¨ve T cell isolation kit (Miltenyi Biotec).
The purity of the population was always higher than 95%. Naı¨ve T
cells were primed with beads coated with anti-CD3 and anti-CD28
(Dynal/Invitrogen) as previously described [44].
Seven days after stimulation, cells were infected by spinocula-
tion. Seven days after infection, cells were reactivated with beads
coated with anti-CD3 and anti-CD28 for 72 h in the presence of
IL-2 at a ratio of 1 bead per cell. The integrase inhibitor 118-D-24
did not have any effect on viral reactivation.
Supporting Information
Figure S1 Recovery and analysis of MBD2 fragment. (A)
Products of PCR amplification using template DNA from J-Lat
6.3 cells. Cells were infected with indicated viruses. For GFP+,
DNA was isolated from GFP-positive cells 4 days post-infection
with the cDNA library. The PCR product corresponding to
MBD21345–1947 is indicated. (B) Electrophoresis of unmethylated
or methylated pEGFP-N1 after incubation with restriction enzyme
Msp I (methylation-insensitive) or Hpa II (methylation-sensitive).
Found at: doi:10.1371/journal.ppat.1000495.s001 (1.53 MB TIF)
Figure S2 Genetic structure of cloned MBD2 fragment. Genetic
structure of MBD21345–1947 clone recovered from screen and full-
length MBD2 mRNA. MBD21345–1947 was cloned into pBMN-
CSI-T as part of cDNA library generation. Dashed lines indicate
portion of MBD2 mRNA cloned into pBMN-CSI-T. Open
inverted triangles indicate predicted translation initiation codons.
Closed inverted triangles indicate translation stop codons. GR,
glycine-arginine repeat region; MBD, methyl-binding domain;
TR, transcriptional repression domain.
Found at: doi:10.1371/journal.ppat.1000495.s002 (0.22 MB TIF)
Figure S3 CpG islands flanking the HIV-1 transcriptional start
site. Nucleotide sequence of first 1000 bases of HIV-1 strain
HXB2 provirus. Locations of CpG islands 1 and 2 are indicated
and highlighted in yellow. Methylation status of CpGs in bold was
determined with bisulfite-mediated methylcytosine mapping. The
U5, R, and U3 regions of the HIV-1 promoter are indicated.
Translation initiation site of Gag polyprotein is indicated. Only
CpG island 2 is conserved in HIV-1 strain NL4-3.
Found at: doi:10.1371/journal.ppat.1000495.s003 (1.33 MB TIF)
Figure S4 HIV-1 CpG islands are methylated during latency
Level of HIV-1 cytosine methylation in J-Lat cell line (A) 6.3, (B)
8.4, (C) 9.2, or (D) 15.4. Data points represent the frequency of
methylation detected for each CpG within the analyzed region. (E)
Frequency of HIV-1 cytosine methylation in J-Lat 6.3 treated with
aza-CdR or PBS as a control. (F) Frequency of HIV-1 cytosine
methylation in purified GFP-negative and -positive populations
after infection of cells with HIV-1 R7/E2/GFP clone. (G)
Frequency of HIV-1 cytosine methylation in latently infected
nonpolarized CD4+ T cells or productively infected Th1, Th2, or
nonpolarized CD4+ T cells. Data points correspond to the
frequency of methylation detected for each CpG within the
analyzed region.
Found at: doi:10.1371/journal.ppat.1000495.s004 (1.13 MB TIF)
Figure S5 Sodium bisulfite conversion is highly efficient Mean
percentage of cytosine-to-thymine conversion in non-CpG dinu-
cleotides by sodium bisulfite treatment of (A) J-Lat cells, (B) Jurkat
cells infected with HIV-1 R7/E2/GFP clone, or (C) CD4+ T
cells. Error bars indicate standard deviation. (D) Results of
bisulfite-mediated methylcytosine mapping of HIV-1 CpG island 2
for additional clones of latently infected CD4+ T cells stimulated
under non-polarizing conditions.
Found at: doi:10.1371/journal.ppat.1000495.s005 (0.62 MB TIF)
Figure S6 Synergistic activation of transcription is specific for
the HIV-1 promoter. Steady-state mRNA levels were measured in
(A) J-Lat 8.4 or (B) J-Lat 9.2. Quantity of HIV-1 (left panel) and
IKB-a (right panel) mRNA was determined by reverse transcrip-
tion and quantitative PCR after indicated treatments. Values are
normalized to the PBS control. Error bars indicate standard
deviation of quantitative PCR results. (C) Flow cytometric analysis
of GFP expression in J-Lat cells after treatment with TNF-a, either
in the presence or absence of cycloheximide. Histograms indicate
GFP fluorescence. Gates indicate GFP-positive cells. (D) Levels of
or HIV-1 (right panel) mRNA were determined by reverse
transcription and quantitative PCR and normalized to cyclophilin
mRNA. Cells were treated with aza-CdR, either in the presence or
absence of cycloheximide. Error bars indicate standard deviation
of qPCR results.
Found at: doi:10.1371/journal.ppat.1000495.s006 (0.79 MB TIF)
Figure S7 Aza-CdR and HDAC inhibitors do not synergistically
reactivate latent HIV-1 Latent HIV-1 reactivation in the indicated
J-Lat cell lines treated with aza-CdR, VPA, aza-CdR plus VPA,
SAHA, or aza-CdR plus SAHA. GFP fluorescence was measured
by flow cytometry and normalized to control cells treated with
DMSO. Experiments were performed in triplicate and error bars
indicate standard deviation.
Found at: doi:10.1371/journal.ppat.1000495.s007 (0.32 MB TIF)
Figure S8 Phenotypic analysis of CD4+ T cells. Flow cytometric
analysis of two donors, (A) and (B), is shown. Expression of CD4
(helper T cell), CD45RA (naı¨ve T cell), CD69 (early activation),
and CD25 (late activation) markers was determined after isolation
and stimulation of naı¨ve T cells. Grey histogram represents cells
incubated with a non-fluorescent isotype control antibody. Data
are representative of those from five different donors.
Found at: doi:10.1371/journal.ppat.1000495.s008 (0.72 MB TIF)
Table S1 Reactivation of latent HIV-1.
Found at: doi:10.1371/journal.ppat.1000495.s009 (0.04 MB
DOC)
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